IN184589B
(pt)
*
|
1996-10-16 |
2000-09-09 |
Alza Corp |
|
US20020182258A1
(en)
*
|
1997-01-22 |
2002-12-05 |
Zycos Inc., A Delaware Corporation |
Microparticles for delivery of nucleic acid
|
US7258869B1
(en)
|
1999-02-08 |
2007-08-21 |
Alza Corporation |
Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
|
AU2046101A
(en)
*
|
1999-11-22 |
2001-06-04 |
Universal Preservation Technologies, Inc. |
Preservation and formulation of bioactive materials for storage and delivery in hydrophobic carriers
|
WO2001066137A1
(en)
*
|
2000-03-07 |
2001-09-13 |
Merck & Co., Inc. |
Adenovirus formulations
|
US7456009B2
(en)
*
|
2000-03-07 |
2008-11-25 |
Merck & Co., Inc. |
Adenovirus formulations
|
US7153472B1
(en)
|
2000-11-22 |
2006-12-26 |
Quadrant Drug Delivery Limited |
Preservation and formulation of bioactive materials for storage and delivery in hydrophobic carriers
|
ATE285756T1
(de)
*
|
2001-06-28 |
2005-01-15 |
Microchips Inc |
Verfahren zum hermetischen versiegeln von mikrochip-reservoir-vorrichtungen
|
US7354597B2
(en)
*
|
2001-12-03 |
2008-04-08 |
Massachusetts Institute Of Technology |
Microscale lyophilization and drying methods for the stabilization of molecules
|
WO2003077861A2
(en)
*
|
2002-03-13 |
2003-09-25 |
Collagenex Pharmaceuticals, Inc. |
Water-based delivery systems
|
WO2004071487A2
(en)
*
|
2002-08-16 |
2004-08-26 |
Microchips, Inc. |
Controlled release device and method
|
WO2004022033A1
(en)
*
|
2002-09-04 |
2004-03-18 |
Microchips, Inc. |
Method and device for the controlled delivery of parathyroid hormone
|
GB2410497B
(en)
*
|
2002-09-27 |
2006-11-22 |
Powderject Res Ltd |
Nucleic acid coated particles
|
EP1551499A1
(en)
|
2002-10-04 |
2005-07-13 |
Microchips, Inc. |
Medical device for neural stimulation and controlled drug delivery
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
EP3597262B1
(en)
|
2002-12-20 |
2023-12-27 |
Xeris Pharmaceuticals, Inc. |
Formulation for intracutaneous injection
|
AU2004229465B2
(en)
*
|
2003-04-09 |
2010-04-29 |
The United States Of America Department Of Veterans Affairs |
Compositions and methods related to production of erythropoietin
|
US20040247671A1
(en)
*
|
2003-04-25 |
2004-12-09 |
Prescott James H. |
Solid drug formulation and device for storage and controlled delivery thereof
|
US7892205B2
(en)
|
2003-06-06 |
2011-02-22 |
Boston Scientific Scimed, Inc. |
Device and method for delivering micronized therapeutic agents in the body
|
WO2005041767A2
(en)
*
|
2003-11-03 |
2005-05-12 |
Microchips, Inc. |
Medical device for sensing glucose
|
US20050267440A1
(en)
*
|
2004-06-01 |
2005-12-01 |
Herman Stephen J |
Devices and methods for measuring and enhancing drug or analyte transport to/from medical implant
|
WO2006015299A2
(en)
*
|
2004-07-30 |
2006-02-09 |
Microchips, Inc. |
Multi-reservoir device for transdermal drug delivery and sensing
|
US7772182B2
(en)
*
|
2004-08-05 |
2010-08-10 |
Alza Corporation |
Stable suspension formulations of erythropoietin receptor agonists
|
US20060029551A1
(en)
*
|
2004-08-05 |
2006-02-09 |
Kui Liu |
Stable particle formulations of erythropoietin receptor agonists
|
WO2006026768A1
(en)
*
|
2004-09-01 |
2006-03-09 |
Microchips, Inc. |
Multi-cap reservoir devices for controlled release or exposure of reservoir contents
|
MX2007002925A
(es)
|
2004-09-10 |
2007-08-14 |
Becton Dickinson Co |
Dispositivo de infusion reconstituyente.
|
US7488316B2
(en)
|
2005-01-25 |
2009-02-10 |
Microchips, Inc. |
Control of drug release by transient modification of local microenvironments
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
WO2006083761A2
(en)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solvent/polymer solutions as suspension vehicles
|
CN101511170B
(zh)
*
|
2005-12-22 |
2014-03-26 |
奥克伍德药业有限公司 |
可升华持续释放传递系统和其制造方法
|
MX2008014870A
(es)
|
2006-05-30 |
2009-02-12 |
Intarcia Therapeutics Inc |
Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
|
EP3421031A1
(en)
|
2006-08-09 |
2019-01-02 |
Intarcia Therapeutics, Inc |
Osmotic delivery systems and piston assemblies
|
DK2134353T3
(en)
*
|
2007-03-30 |
2017-02-20 |
Helix Biopharma Corp |
TWO-PHASE LIPID VESICLE COMPOSITION AND METHOD OF TREATING CERVIC DYSPLASY BY INTRAVAGINAL ADMINISTRATION
|
CN101715340A
(zh)
|
2007-04-23 |
2010-05-26 |
精达制药公司 |
促胰岛素释放肽的混悬制剂及其应用
|
US8968786B2
(en)
|
2007-06-22 |
2015-03-03 |
Board Of Regents, The University Of Texas System |
Formation of stable submicron peptide or protein particles by thin film freezing
|
EP2240155B1
(en)
|
2008-02-13 |
2012-06-06 |
Intarcia Therapeutics, Inc |
Devices, formulations, and methods for delivery of multiple beneficial agents
|
EP2376522A4
(en)
|
2008-11-16 |
2013-12-25 |
Univ Texas |
LOW VISCOSIS HIGHLY CONCENTRATED SUSPENSIONS
|
EP2398466B1
(en)
*
|
2008-11-24 |
2021-02-17 |
Massachusetts Institute of Technology |
Methods and compositions for localized nanoparticle delivery to a tumor
|
SI2462246T1
(en)
|
2009-09-28 |
2018-01-31 |
Intarcia Therapeutics, Inc. |
Fast-setting and / or cessation of substantially unchanged delivery of the product
|
US20110223208A1
(en)
|
2010-03-09 |
2011-09-15 |
Beth Hill |
Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
|
US9072668B2
(en)
|
2010-03-09 |
2015-07-07 |
Janssen Biotech, Inc. |
Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
|
EP2544721B1
(en)
*
|
2010-03-09 |
2017-12-06 |
Janssen Biotech, Inc. |
Non-aqueous high concentration reduced viscosity suspension formulations
|
CA2788060C
(en)
|
2010-03-17 |
2017-07-11 |
Novaliq Gmbh |
Pharmaceutical composition for treatment of increased intraocular pressure
|
US20120046225A1
(en)
|
2010-07-19 |
2012-02-23 |
The Regents Of The University Of Colorado, A Body Corporate |
Stable glucagon formulations for the treatment of hypoglycemia
|
EP2444063A1
(en)
|
2010-10-20 |
2012-04-25 |
Novaliq GmbH |
Liquid pharmaceutical compositions for the delivery of active ingredients
|
EP2462921A1
(en)
|
2010-11-11 |
2012-06-13 |
Novaliq GmbH |
Liquid pharmaceutical compositions for the treatment of a posterior eye disease
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
DK2683364T3
(en)
|
2011-03-10 |
2017-02-27 |
Xeris Pharmaceuticals Inc |
Stable formulations for parenteral injection of peptide drugs.
|
EP2714008B1
(en)
|
2011-05-25 |
2016-12-14 |
Novaliq GmbH |
Pharmaceutical composition for administration to nails
|
CN107397718A
(zh)
|
2011-05-25 |
2017-11-28 |
诺瓦利克有限责任公司 |
基于半氟化烷烃类的外用药物组合物
|
EA027744B1
(ru)
|
2011-10-31 |
2017-08-31 |
Ксерис Фармасьютикалс, Инк. |
Лекарственные формы для лечения сахарного диабета
|
KR101989648B1
(ko)
|
2012-01-23 |
2019-06-14 |
노바리크 게엠베하 |
부분불소화 알칸에 기초한 안정화된 단백질 조성물
|
US9125805B2
(en)
|
2012-06-27 |
2015-09-08 |
Xeris Pharmaceuticals, Inc. |
Stable formulations for parenteral injection of small molecule drugs
|
JP6352266B2
(ja)
|
2012-09-12 |
2018-07-04 |
ノバリック ゲーエムベーハー |
半フッ化アルカンの混合物を含む組成物
|
EP3181119B1
(en)
|
2012-09-12 |
2019-07-10 |
Novaliq GmbH |
Semifluorinated alkane compositions for use in the treatment of keratoconjunctivitis sicca
|
US9505737B2
(en)
|
2013-01-11 |
2016-11-29 |
Corsair Pharma, Inc. |
Treprostinil derivative compounds and methods of using same
|
EP2943479B1
(en)
|
2013-01-11 |
2020-04-15 |
Corsair Pharma, Inc. |
Prodrugs of treprostinil
|
US9018162B2
(en)
|
2013-02-06 |
2015-04-28 |
Xeris Pharmaceuticals, Inc. |
Methods for rapidly treating severe hypoglycemia
|
SG11201505926VA
(en)
|
2013-03-15 |
2015-09-29 |
Biogen Ma Inc |
Factor ix polypeptide formulations
|
BR112016001522B1
(pt)
|
2013-07-23 |
2019-10-01 |
Novaliq Gmbh |
Composições de anticorpo estabilizado
|
US8986732B2
(en)
|
2013-08-12 |
2015-03-24 |
Helix Biopharma Corporation |
Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
|
US10159646B2
(en)
|
2013-08-12 |
2018-12-25 |
Altum-Avro Pharma Partnership |
Biphasic lipid-vesicle compositions and methods for treating cervical dysplasia by intravaginal delivery
|
KR102435648B1
(ko)
|
2013-09-11 |
2022-08-25 |
이글 바이오로직스 인코퍼레이티드 |
점도저하제를 함유하는 액체 단백질 제형
|
EP3049114B1
(en)
|
2013-09-27 |
2021-11-10 |
Massachusetts Institute of Technology |
Carrier-free biologically-active protein nanostructures
|
BR112016021777A2
(pt)
*
|
2014-03-24 |
2017-10-03 |
Biogen Ma Inc |
Formulações de fator ix liofilizado
|
WO2016010538A1
(en)
|
2014-07-16 |
2016-01-21 |
Corsair Pharma, Inc. |
Treprostinil derivative compounds and methods of using same
|
CA2957399C
(en)
|
2014-08-06 |
2023-09-26 |
Xeris Pharmaceuticals, Inc. |
Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
US11471479B2
(en)
|
2014-10-01 |
2022-10-18 |
Eagle Biologics, Inc. |
Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
|
KR102650751B1
(ko)
|
2015-06-03 |
2024-03-22 |
인타르시아 세라퓨틱스 인코포레이티드 |
임플란트 배치 및 제거 시스템들
|
US9649364B2
(en)
|
2015-09-25 |
2017-05-16 |
Xeris Pharmaceuticals, Inc. |
Methods for producing stable therapeutic formulations in aprotic polar solvents
|
US9394227B1
(en)
|
2015-06-17 |
2016-07-19 |
Corsair Pharma, Inc. |
Treprostinil derivatives and compositions and uses thereof
|
US9643911B2
(en)
|
2015-06-17 |
2017-05-09 |
Corsair Pharma, Inc. |
Treprostinil derivatives and compositions and uses thereof
|
AU2016305087B2
(en)
|
2015-08-12 |
2022-01-20 |
Massachusetts Institute Of Technology |
Cell surface coupling of nanoparticles
|
US11590205B2
(en)
|
2015-09-25 |
2023-02-28 |
Xeris Pharmaceuticals, Inc. |
Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
|
WO2017055454A1
(en)
|
2015-09-30 |
2017-04-06 |
Novaliq Gmbh |
Semifluorinated compounds and their compositions
|
ES2803248T3
(es)
|
2015-09-30 |
2021-01-25 |
Novaliq Gmbh |
2-perfluorohexil octano para administración oftálmica
|
SG10201913699QA
(en)
|
2016-05-16 |
2020-03-30 |
Intarcia Therapeutics Inc |
Glucagon-receptor selective polypeptides and methods of use thereof
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
WO2017218533A1
(en)
|
2016-06-13 |
2017-12-21 |
Torque Therapeutics, Inc. |
Methods and compositions for promoting immune cell function
|
PL3442480T3
(pl)
|
2016-06-23 |
2020-04-30 |
Novaliq Gmbh |
Sposób podawania miejscowego
|
MX2019003363A
(es)
|
2016-09-22 |
2019-10-02 |
Novaliq Gmbh |
Composiciones farmaceuticas para usarse en la terapia de la blefaritis.
|
EP3515467B1
(en)
|
2016-09-23 |
2023-11-29 |
Novaliq GmbH |
Ophthalmic compositions comprising ciclosporin
|
AU2018206539A1
(en)
|
2017-01-03 |
2019-07-18 |
Intarcia Therapeutics, Inc. |
Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
|
AU2018253944B2
(en)
|
2017-04-21 |
2022-09-15 |
Dermaliq Therapeutics, Inc. |
Iodine compositions
|
WO2018206656A1
(en)
|
2017-05-12 |
2018-11-15 |
Novaliq Gmbh |
Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
|
WO2018211517A1
(en)
|
2017-05-16 |
2018-11-22 |
Bhami's Research Laboratory, Pvt. Ltd. |
High concentration protein formulations with reduced viscosity
|
EP3630061B1
(en)
|
2017-06-02 |
2024-04-03 |
Xeris Pharmaceuticals, Inc. |
Precipitation resistant small molecule drug formulations
|
AU2018328209A1
(en)
|
2017-09-05 |
2020-04-23 |
Torque Therapeutics, Inc. |
Therapeutic protein compositions and methods of making and using the same
|
CN111372566A
(zh)
|
2017-09-27 |
2020-07-03 |
诺瓦利克有限责任公司 |
用于治疗眼部疾病的包含拉坦前列素的眼科用组合物
|
WO2019068763A1
(en)
|
2017-10-04 |
2019-04-11 |
Novaliq Gmbh |
OPHTHALMIC COMPOSITIONS COMPRISING F6H8
|
MX2020009132A
(es)
|
2018-03-02 |
2020-12-11 |
Novaliq Gmbh |
Composiciones farmaceuticas que comprenden nebivolol.
|
WO2019217637A1
(en)
*
|
2018-05-09 |
2019-11-14 |
Biomatrica, Inc. |
Stabilization of proteins in biological samples
|
AU2019358249B2
(en)
|
2018-10-12 |
2024-02-22 |
Novaliq Gmbh |
Ophthalmic composition for treatment of dry eye disease
|
CN113661006A
(zh)
|
2019-02-05 |
2021-11-16 |
林迪生物科学公司 |
分离的细胞培养物组分以及用于从液体细胞培养基中分离其的方法
|
WO2021109979A1
(en)
*
|
2019-12-06 |
2021-06-10 |
Guangzhou Bioseal Biotech Co., Ltd. |
Flowable fibrinogen thrombin paste
|
US20230101362A1
(en)
*
|
2021-09-16 |
2023-03-30 |
Team Medical Llc |
Rna stabilization
|